System Biosciences Announces License of ExoQuick® Technology to QIAGEN | System Biosciences

Home|Blog|SystemBiosciencesAnnouncesLicenseofExoQuick®TechnologytoQiagen

PRESSRELEASE:SystemBiosciences(SBI),aleADIngproviderofexosomeresearchtoolsandservices,

announcedtodaythatQIAGEN,aleadingglobalproviderofSampletoInsightssolutionsformoleculardiagnosticsandlifesciences,hassignedanon-exclusive,worldwidelicenseforSBIspatentedExoQuick®technologyforresearchuse.QIAGENintendstousetheExoQuicktechnologyinprecipitation-basedmiRCURY™productscomplementingitsleadingportfolioofspincolumn-basedexoEasyandexoRNeasyproductlines.

QIAGENslicensedemonstratesthevalueofExoQuicktechnologyforhigh-throughput,scalableisolationofexosomesfromarangeofbiofluidsamples,saidJakeLesnik,VicePresidentofCommercialDevelopmentatSBI.ThelicenseagreementalsodemonstratesSBI’scommitmenttoprotectingitsproprietaryExoQuicktechnology,whichisusedbythousandsofresearchersgloballyforfastandefficientexosomeisolation.

Oncethoughttobelittlemorethanawayforcellstooffloadwaste,exosomes(smallextracellularvesiclesranginginsizefrom30–200nm)arearapidlyexpandingareaofstudyinbasicresearch,bioMarkerdiscoveryandtherapeuticdelivery.Theseextracellularvesiclesfunctionassignalcarriersandtissuere-shapersthroughtheircargoofRNA,proteins,andlipids,andareinvolvedinawiderangeofhealthyandpathogenicprocessesincludingcancer,inflammation,immunity,CNSfunction,andcardiaccellfunction.Exosomesarefoundinawiderangeofbiofluids,includingserum,plasma,ascitesfluid,urine,salivaandtissueculturemedia,andareconsideredarichsourceofmaterialforbiomarkerdiscovery,includingforliquidbiopsydiagnosticdevelopment.

In2009,theteamatSBIrecognizedthegreatpotentialofexosomesanddevelopedthefirstcommercialexosomeisolationkit,ExoQuick.Intheinterveningyears,theExoQuickfamilyofproductshasgoneontobecitedinover600peer-reviewedscientificpublications,makingitthemostpublishedexosomeisolationreagentintheworld.SBIremainsfocusedonrefiningandenhancingitsexosomeisolationtechnologytocontinuetosupportthegrowingexosomeresearchcommunity.

AboutSystemBiosciences(SBI)

SystemBiosciences(SBI),aPaloAlto,CA-basedlifescienceresearchreagentscompany,isagloballeaderinprovidingexosomeresearchtechnology,withanextensiveportfolioofexosomeresearchtoolsandservices. InadditiontoExoQuickandExoQuick-TC®,SBIoffersabroadrangeofreagentsandservicesforexosomecharacterization,biomarkerdiscoveryandengineering,includingExoFBS™,ExoFlow™,Exo-fect™,andExoGlow™technologies,aswellasExo-NGS™andExoMS™servicesforexosomalRNA-Seqandproteomicsanalysis,respectively. SBIisalsoapioneeringenedeliverytechnologies,includinglentiviral,Minicircle,piggyBac™andothergenedeliveryplatforms.Formoreinformation,visittheSBIwebsiteatwww.systembio.com.

AboutQIAGEN

QIAGENN.V.,aNetherlands-basedholdingcompany,istheleadingglobalproviderofSampletoInsightsolutionsthatenablecustomerstogainvaluablemolecularinsightsfromsamplescontainingthebuildingblocksoflife.OursampletechnologiesisolateandprocessDNA,RNAandproteinsfromblood,tissueandothermaterials.AssaytechnologiesmakethesebiomoleculesvisIBLeandreadyforanalysis.Bioinformaticssoftwareandknowledgebasesinterpretdatatoreportrelevant,actionableinsights.Automationsolutionstiethesetogetherinseamlessandcost-effectiveworkflows.QIAGENprovidessolutionstomorethan500,000customersaroundtheworldinMolecularDiagnostics(humanhealthcare),AppliedTesting(primarilyforensics),Pharma(pharmaandbiotechcompanies)andAcademia(lifesciencesresearch).AsofDecember31,2017,QIAGENemployedapproximately4,700peopleinover35locationsworldwide.Furtherinformationcanbefoundathttp://www.qiagen.com.

SystemBiosciences(SBI)appreciatesthecriticalrolethatyouandourproductsandservicesplayinresearcheffortstofurtherscientificinnovationanddiscovery.Basedonthenatureofourbusinessandtheproductsandservicesweprovide,SystemBioscienceswillremainopenduringtheCOVID-19pandemictosupportCOVID-19andotheressentialbiomedicalresearch.Manyofouremployeesareworkingremotely,whileouressentialon-siteemployeesareworkingastaggeredscheduleandfollowingsocialdistancingguidelines.

WearecontinuallyassessingourmanufacturingandsuppliercapABIlitiesduringtheCOVID-19situationandareimplementingprecautionarymeasurestoensureuninterruptedsupplyofSBIproductsandservices.Currently,andasweabidebylocalshelterinplaceorders,wearefullyoperationalanddonotanticipateanymaterialsupplydisruptionsforourproducts.Asthesituationevolves,ourgoalistoutilizepreventivemeasurestoreducethethreatthatCOVID-19posestoourabilitytomeettheneedsofourcustomersglobally.